Schistosomiasis is a parasitic infection caused by freshwater flatworms, and for more than four decades the drug praziquantel has been the backbone of its treatment worldwide. This article explains what the disease actually is, how it is contracted and diagnosed, why praziquantel became the standard of care, what the clinical evidence does and does not show, how it is dosed in practice, and what a patient should realistically expect during and after treatment.

What Schistosomiasis Is, and How People Actually Get It

Schistosomiasis, sometimes called bilharzia, is caused by several species of Schistosoma blood flukes, most importantly S. mansoni, S. haematobium, and S. japonicum. The parasite has a life cycle that depends on freshwater snails. Infected people or animals pass eggs in urine or stool; if these reach fresh water, the eggs hatch and infect a specific species of snail, inside which the parasite multiplies and eventually releases free-swimming larvae called cercariae. These larvae penetrate intact human skin during wading, swimming, bathing, or agricultural work in contaminated lakes, rivers, or irrigation canals. Once inside the body, the larvae mature into adult worms that live in the blood vessels around the intestines or bladder, mating and producing eggs for years.

This life cycle explains something readers often ask: schistosomiasis is not contagious in the way a cold or flu is. It cannot spread directly from person to person through touch, coughing, or ordinary household contact, and it is not sexually transmitted in any meaningful epidemiological sense. Infection requires contact with fresh water that harbors the correct snail host and has been contaminated with human or animal waste. This is why the disease clusters tightly around specific rivers, lakes, and irrigation systems in parts of sub-Saharan Africa, the Middle East, Southeast Asia, South America, and the Caribbean, and why travelers who avoid freshwater swimming in these regions are very unlikely to acquire it.

Recognizing It: Symptoms and Diagnosis

Many infections, especially light ones, cause no noticeable symptoms at first. Some travelers develop an itchy rash, sometimes called swimmer's itch, within hours of skin penetration. Weeks later, as the maturing worms trigger an immune reaction, a subset of people develop acute schistosomiasis, also called Katayama syndrome: fever, fatigue, muscle aches, hives, cough, and abdominal discomfort, often accompanied by a marked rise in eosinophils on blood testing. Chronic infection, which develops over months to years as eggs become trapped in tissue and provoke inflammation and scarring, can cause blood in the urine and bladder damage with S. haematobium, or abdominal pain, diarrhea, enlarged liver and spleen, and in advanced cases portal hypertension with S. mansoni and S. japonicum. Long-standing urinary schistosomiasis is also recognized as a risk factor for bladder cancer.

Diagnosis rests on finding the parasite's eggs under a microscope, in stool for intestinal species and in urine for S. haematobium, typically using a standardized counting technique such as the Kato-Katz method for stool. Because egg output can be intermittent and light infections are easy to miss on a single sample, clinicians often request repeat specimens. Blood antibody tests are useful for travelers recently exposed, since antibodies can be detected before eggs appear, though they cannot distinguish a current infection from a past, already-treated one. Newer PCR-based stool and urine tests are more sensitive and are increasingly used in research and some clinical settings, though they are not yet universally available.

Why Praziquantel Became the Standard Treatment

Praziquantel is a synthetic pyrazinoisoquinoline compound, developed in the 1970s through a collaborative research program involving the German companies Bayer and E. Merck, building on academic parasitology work of the period. It was a genuine advance: earlier antischistosomal drugs, including antimony-based compounds, were toxic and difficult to administer. Praziquantel, by contrast, could be given orally, in a single day, with a good safety margin. It is now on the World Health Organization's Model List of Essential Medicines and is the only drug WHO currently recommends for both individual treatment and mass preventive chemotherapy campaigns, which have delivered treatment to well over a hundred million people annually in endemic countries in recent years, according to WHO program reporting.

The drug works by disrupting calcium regulation across the worm's outer covering, the tegument. This causes rapid, sustained muscle contraction (tetanic paralysis) of the adult worm and damages the tegument itself, exposing hidden parasite antigens to the host's immune system, which then helps clear the dying worms. This mechanism has been characterized in laboratory and animal studies over several decades and is well accepted, though the precise molecular target on the parasite was only more fully clarified in more recent pharmacological research.

Human evidence for efficacy is substantial. Randomized controlled trials conducted across endemic regions in Africa, Asia, and South America, and synthesized in systematic reviews carried out under the Cochrane Infectious Diseases Group, consistently show that a single oral dose produces cure, meaning no eggs detectable on follow-up testing, in a majority of patients, with figures in published trials commonly falling in the range of roughly 60 to 90 percent depending on the species treated, the intensity of infection, and how soon after treatment follow-up testing is done. Importantly, even when a single dose does not achieve complete parasitological cure, it reliably produces a large reduction in egg output, typically well above 90 percent, which is clinically meaningful because egg-related inflammation drives most of the disease's long-term damage. The Cochrane reviewers have also noted a genuine limitation worth stating plainly: praziquantel is far less effective against the young, migrating stage of the parasite (the schistosomulum) than against mature adult worms. This is why a person treated during the early, acute phase of infection may need a second dose several weeks later, once the parasites have matured enough for the drug to work fully against them.

Dosing in Practice

Under the brand name Biltricide and various generics, praziquantel is manufactured as a scored tablet, and dosing is calculated by body weight rather than given as a flat dose. WHO and most national guidelines recommend:

Tablets are taken with food, which improves tolerability, and are swallowed without chewing, since the drug has a strongly bitter taste that can trigger gagging if it lingers in the mouth. Absorption is rapid, with peak blood levels typically reached within one to three hours, and the drug is largely cleared from the body within a day, which is why a single day's dosing is enough to expose adult worms to an effective concentration.

People sometimes ask how quickly praziquantel "works." The pharmacological action against adult worms begins within hours of dosing, and most patients notice improvement in acute symptoms like fever or abdominal discomfort within days. But egg clearance is slower and less dramatic: eggs already trapped in tissue continue to be shed in stool or urine for some weeks after the adult worms have died, so a stool or urine test done immediately after treatment is not a reliable way to judge success. Clinicians generally recheck egg counts four to twelve weeks after treatment to assess cure. There is no reliable evidence supporting home remedies, herbal preparations, or over-the-counter products as substitutes for this drug; schistosomiasis is a tissue-invasive parasitic infection that will not resolve on its own and should be managed with a physician's guidance and laboratory-confirmed diagnosis, not self-treated.

Side Effects, Follow-Up, and Honest Limits

Praziquantel is generally well tolerated. The most commonly reported effects in clinical trials are transient abdominal pain, nausea, dizziness, headache, and fatigue, usually appearing within hours of dosing and resolving within a day or two. A minority of patients develop urticaria or itching, which is thought to reflect the immune response to antigens released from dying worms rather than a direct drug reaction. WHO guidance does not list pregnancy as a contraindication, and current recommendations support treating pregnant and breastfeeding women in endemic settings when infection is confirmed, since untreated infection carries its own risks; as always, this is a decision to make with one's own physician weighing individual circumstances.

Two honest caveats deserve mention. First, praziquantel does not prevent reinfection; anyone who returns to contaminated water afterward can become infected again, which is why control programs pair treatment with efforts to reduce water contact and improve sanitation. Second, researchers have documented isolated cases and some laboratory evidence of reduced parasite susceptibility to praziquantel, raising theoretical concern about drug resistance emerging under the pressure of mass treatment programs. This remains an area of active monitoring by parasitologists rather than an established clinical problem at this time, and it is one reason WHO and academic research groups continue to study alternative and combination therapies, though none has yet displaced praziquantel as first-line treatment.

None of this diminishes what the drug has accomplished. A single day's treatment, costing very little, curing most infections outright and dramatically reducing disease burden in the rest, represents a remarkable return on decades of patient laboratory and clinical research. It is also a reminder that good stewardship of one's own health, and one's family's, means using well-tested tools properly rather than either ignoring a real infection or reaching for unproven remedies out of impatience. A physician who can confirm the diagnosis, calculate an accurate weight-based dose, and arrange sensible follow-up testing remains the safest path from suspected exposure to confirmed cure.

Key takeaway: Praziquantel, given as a correctly weight-dosed single-day course under a physician's care, remains the well-evidenced, WHO-recommended cure for schistosomiasis, though follow-up testing and attention to reinfection risk matter as much as the dose itself.